Meeting
2015 ASCO Annual Meeting
Total pathologic complete response (tpCR) and event-free survival (EFS) with subcutaneous (SC) or intravenous (IV) trastuzumab in HER2-positive early breast cancer (EBC).
Authors
Christian Jackisch
Sana Klinikum Offenbach GmbH, Offenbach, Germany
Christian Jackisch , Roberto Hegg , Daniil Stroyakovskiy , Jin Seok Ahn , Bohuslav Melichar , Shin-Cheh Chen , Aulde Crepelle-Flechais , Dominik Heinzmann , Mona Shing , Xavier B. Pivot
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Clinical Trial Registration Number
NCT00950300
Citation
J Clin Oncol 33, 2015 (suppl; abstr 585)
DOI
10.1200/jco.2015.33.15_suppl.585
Abstract #
585
Poster Bd #
74
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Double-blind, randomized phase III study to compare the efficacy and safety of CT-P6, trastuzumab biosimilar candidate versus trastuzumab as neoadjuvant treatment in HER2 positive early breast cancer (EBC).
First Author: Justin Stebbing
Poster
2022 ASCO Annual Meeting
Assessing response to neoadjuvant docetaxel and trastuzumab in Nigerian women with HER2-positive breast cancer (ARETTA).
First Author: Atara Isaiah Ntekim
Poster
2017 ASCO Annual Meeting
A randomized, double-blind, phase III study comparing SB3 (trastuzumab biosimilar) with originator trastuzumab in patients treated by neoadjuvant therapy for HER2-positive early breast cancer.
First Author: Xavier B. Pivot
Poster
2016 ASCO Annual Meeting
Tolerability and effectiveness of pertuzumab-containing neoadjuvant (NA) regimens vs. AC-TH for HER2-positive (+) localized breast cancer (BC).
First Author: Laura Spring